Dec 13 (Reuters) - Imugene Ltd IMU.AX
* Imugene broadens pipeline with acquisition of immuno-oncology technology from Melbourne's Baker IDI heart and diabetes institute
* Baker IDI will receive 1.5 per cent of net revenues generated from approved cancer therapies using technology
* Imugene will pay no upfront costs for exclusive, worldwide rights to baker IDI's arginine modulators
* Acquisition of immuno-oncology technology-imu.ax Source text for Eikon: ID:nASX9pkwwf Further company coverage: IMU.AX